載入中
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
前收盤價
US$31.10
−US$0.02 · -0.06%
盤前
US$32.6132
+US$1.5132 · +4.87%
10月12日 上午4:06 ET
盤中時間採用ET。市場資料可能有所延遲。
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
日內區間
目前US$31.10
52週區間
目前US$31.10
盤中時間採用ET。市場資料可能有所延遲。
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
日內區間
目前US$31.10
52週區間
目前US$31.10
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
iShares Biotechnology ETFIBB797.37萬0.08%108.2億 USD0.44%US$206.49+3.00%
iShares Core MSCI EAFE ETFIEFA405.09萬0.00%1894.71億 USD0.07%US$96.52+0.68%
iShares MSCI EAFE Small-Cap ETFSCZ261.19萬0.02%128.85億 USD0.40%US$83.93+0.82%
iShares MSCI Netherlands ETFEWN164.37萬0.23%7.02億 USD0.50%US$66.64+0.70%
Fidelity Nasdaq Composite Index ETFONEQ81.24萬0.01%109.4億 USD0.21%US$107.81+0.63%
iShares International Country Rotation Active ETFCORO40.41萬0.00%131.46億 USD1.06%US$36.17+0.61%
Virtus Biotech Clinical Trials ETFBBC32.15萬0.78%4099.65萬 USD0.65%US$44.1456+2.08%
Fidelity Disruptive Medicine ETFFMED22.1萬0.45%5231萬 USD0.50%US$31.4003+2.73%iShares Biotechnology ETFIBBiShares Core MSCI EAFE ETFIEFAiShares MSCI EAFE Small-Cap ETFSCZiShares MSCI Netherlands ETFEWNFidelity Nasdaq Composite Index ETFONEQiShares International Country Rotation Active ETFCOROVirtus Biotech Clinical Trials ETFBBCFidelity Disruptive Medicine ETFFMEDAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
